í I	REVIEW BOARD ON TH	E USE	OF	HUMAN	SUBJE	CTS: ICDDR,8.	99
	Investigator Shahjahan					estigator (if any)	
Л			***			Agency (if Non-ICDD)	₹,₿)
le of	Study Composition and		-	Project (
munol	ogical properties of the ou	ıter		(-)		inuation with change	
	ne proteins of Vibrio chol			()	No ci	nange (do not fill o	ut rest of form
				· ·			The second section of the second seco
cle th	e appropriate answer to	each	of	the fo	llowi	ng (If Not Applicabl	e write NA).
	e of Population: NA	i.		5.	Will	signed consent torm	be required:
	Ill subjects	Yes	No		(a)		
(b)	Non-ill subjects	Yes	No		(b)	From parent or guar	dian
(c)	Minors or persons			')		(if subjects are mi	
	under guardianship	Yes	No	6.	Will	precautions be take	
1	the study involve: N	A			anon	ymity of subjects	Yes No
	Physical risks to the	• •		7	Chec	k documents being su	bmitted herewith
1	subjects	Yes	No		Boar	đ:	
(b)	Social Risks	Yes	No			Umbreila proposal -	Initially submi
	Psychological risks				to with magnetic angles of	overview (all other	requirements wi
Ì	to subjects	Yes	No			be submitted with i	
(ii)	-	Yes	No			Protocol (Required)	
	Invasion of privacy	Yes	No		a Philipson are v	Abstract Summary (F	Required)
	Disclosure of informa-					Statement given or	
i	tion damaging to sub-					nature of study, r	sks, types of a
-	ject or others	Yes	No			ions to be asked, a	
ປິດຂວ	the study involve:	P.				to participate or	
	Use of records, (hosp-					Informed consent for	
3; -	ital, medical, death,			•	h-maga-a-rheim m	Informed consent fo	
.!	birth or other)	Yes	No			guardian	
(b)	Use of fetal tissue or					Procedure for maint	saining confiden-
	abortus	Yes	No		*******	ity	
(c)	Use of organs or body					Questionnaire or in	iterview schedu
Ĭ,	fluids	Yes	No		* TF	the final instrumer	
Acre s	subjects clearly informe					ior to review, the	-
(£1)	Nature and purposes of				-	ould be included in	-
] '	study	Yes	No		1.		
(b)	Procedures to be				-0 F	covered in the que	
	followed including					interview which co	
į	alternatives used	Yes	No			either sonsitive	
(c)	Physical risks	Yes	No			constitute an invi	
(d)	Sensitive questions	Yes	No		2.		
(e)	Benefits to be derived	Yes	No			questions to be a	
(£)	Right to refuse to		- 5 - 7			areas.	
	participate or to with-				3.		to when the ques-
	draw from study	Yes	No		•	naire will be pre	
(g)	Confidential handling					for review.	
1	of data	Yes	No			•	
(h)	Compensation 6/or treat					•	
1	ment where there are ri						•
	or privacy is involved					.,	•
	MIN nambicular maccaium			Ma			

Investigator

Trainee

agree to obtain approval of the Review Board on the Use of Human Subjects for any connections the rights and welfare of subjects before making such change.

SECTION I - RESEARCH PROTOCOL

- 1. <u>Title</u>: Composition and Immunological properties of the outer membrane proteins of <u>Vibrio cholerae</u>.
- 2. Principal Investigator: Shahjahan Kabir
- 3. Starting Date: March, 1980
- 4. Completion Date: February, 1981.
- 5. Total Direct Cost : \$ 18,600.00
- 6. Availability of funds:
 - a) Scientific Director's Remarks:
 - b) Controller's Remarks:

7. Abstract Summary:

The study plans to analyse the outer membrane proteins of Vibrio cholerae from several strains belonging to both the biotypes (classical and El Tor) and the serotypes (Ogawa and Inaba). Vibrio cholerae will be grown under various cultural conditions. Membrane proteins will be isolated from the bacteria by sequential treatment with lysozyme and Triton X-100. The composition of the membrane proteins will be analysed by polyacrylamide gel electrophoresis in the presence of sodium dodecyl suiphate. Antisera to the outer membrane proteins will be raised in rabbits and the immunochemical composition of the outer membrane proteins will be analysed by immunodiffusion and immunoelectrophoresis. The prophylactic potential of the outer membrane proteins would be studied in rabbits against experimental cholera. Rabbits immunised with the outer membrane proteins will be challenged with live vibrios of both biotypes and serotypes. The degree of protection will be measured by the intestinal fluid

response in the ligated iteal loops. The prophylactic potential of the outer membrane proteins would be compared with those of the whole cell vaccine and the cholera toxoid.

8.	Rev	<u>iews :</u>
	a)	Research involving human subjects:
	b)	Research Committee :
	c)	Director:
	d)	BMRC:
	۵۱.	Controller/Administrator:

A. INTRODUCTION

to control diarrhoeal disease caused by the toxin-secreting, non-invasive bacteria such as Vibrio cholerae through immunological research and vaccine development. Hence, research will be carried out to develop new and improved immunogens with primary emphasis on those obtained from bacterial somatic structures. Experiments will be performed on small laboratory animals to determine the protective capacity of the somatic antigens against cholera. It is anticipated that information obtained from such studies will make significant contribution to the design of studies to immunise human beings against enteric bacterial infections.

Background: Vibrio cholerae, the causative agent of cholera, is a Gram-negative bacterium which colonises the small intestine. It secretes an exotoxin which binds to the ganglioside receptor and causes an outpouring of the fluid into the gut lumen. The currently available vaccine against cholera is partly effective for a short duration.

In cholera endemic areas the population acquires a significant degree of specific immune protection due to exposure to Vibrio cholerae antigens(1). Thus it has been observed that with increasing age the rate of reinfection is lowered as well as the incidence of the disease. Also, from volunteer studies it has been observed that convalescents from induced cholera were resistant to homologous challenge for upto 12 months(2). These findings suggest that it should be possible to induce effective immunity against cholera.

Both antibacterial as well as antitoxic immunity are developed in the host after an infection of cholera(3, 4). Although there are controversies as to the relative protection provided by antibacterial versus antitoxic immunity, recent studies on the immunity against cholera in man indicated that the predominant immune mechanism was antibacterial rather than antitoxic in nature(5). This was based on the findings that although purified cholera toxoid was antigenic when administered parenterally and orally, it failed to provide protection against challenge. However, clinical cholera conferred formidable protection against both homologous and heterologous challenge.

Cholera vaccines, composed of killed vibrios and administered parenterally, do induce immunity. However, the protective capacity is of limited duration, being 40-60% during the first 2 months and 10-20% after 6 months (1, 6). Besides, the whole cell vaccines are known to be reactigenic i.e., induce pain and fever.

Cell wall antigens consisting mainly of lipopolysaccharides (LPS) of both Ogawa and Inaba serotypes have been isolated and tried in the field (7). The Inaba antigen and the whole cell monospecific Inaba vaccines gave protection against infection by Vibrio cholerae Inaba El Tor biotype. The monovalent Ogawa vaccine was ineffective although it induced vibriocidal antibody titer rises against both Ogawa and Inaba serotypes. In: a field trial conducted in the Philippines, significant protection was provided by a monovalent Inaba whole cell vaccine against Ogawa infections (8). These results indicate that Ogawa vaccines do not confer protection against infection by loaba. However, loaba vaccines cross protect against Ogawa infections. Both the whole cell vaccine as well as the LPS enriched antigen can induce fever and pain in the host. Considering all these problems associated with the currently available cholera vaccines it would be desirable to have

a new and improved somatic antigen which would(a) be nontoxic

(b) cross protect against all biotypes and serotypes and (c) confer

longer immunity.

The Protein antigens of Vibrio cholerae:

Vibrio cholerae, like other Gram-negative bacteria such as

Escherichia coli, possesses three distinct layers: the outer

membrane, the inner or cytoplasmic membrane and the

peptidoglycan(9). The outer membrane contains surface components

such as proteins and lipepolysaccharides and it is most likely

that these components would interact with the host in order to

elicit antibacterial immune response.

Proteins comprise about half the weight of 'the outer membrane of Gram-negative bacteria. There is evidence in the literature that protein antigens shared by both Inaba and Ogawa serotypes might contribute to the vibriccidal activity in antisera raised against live vibrios(10). But, these authors did not characterise the protein antigens. Besides, very little is known about the composition and immunological properties of the outer membrane of Vibrio cholerae.

Structure of the outer membrane of Gram-negative bacteria: The outer membrane of Gram-negative bacteria is composed of proteins. phospholipids and LPS, the relative amounts of which depend on growth conditions. The protein composition of the outer membrane is relatively simple and depending on the strain and growth conditions. 16 to 25 protein bands are usually resolved by SDS-polyacrylamide gel electrophoresis. However, two or five polypeptides are present in greatest amount. These include three or four proteins with molecular weights in the range of 40,000. These proteins are resistant to solubilisation in SDS and depending on the temperature of solubilisation exhibit different mobilities during electrophoresis. In addition to these major outer membrane proteins of higher molecular weights another major protein called lipoprotein is present several Gram-negative bacteria(11). This protein exists in both bound and free-form and has been detected in Escherichia <u>coli</u> Salmonella and Shigella.

Outer membrans proteins as immunogens:

There are several studies related to the composition of the cuter membrane proteins of Gram-negative bacteria such as Escherichia coli and Salmonella(12). But, comparatively little is known about

outer membrane proteins of Escherichia coli and Salmonella can act as surface antigens (13, 14, 15). Thus autisers raised against the outer membrane proteins of Salmonella have been found to render protection against experimental Salmonellosis (16). Also, antigenic cross reactivity among several serotypes of E. coli.

Salmonella typhimurium and Shigella have been reported (14).

Recently, Geyer et al(17) have isolated a LPS-binding cell surface protein from Salmonella minnesota which cross reacted with several enteric strains such as Salmonella typhimurium, E. coli and Shigella. These findings suggest that some of the outer membrane proteins of Gram-negative bacteria because of their presence on the cell surface possess antigenic properties.

Preliminary studies (18):

There are two blotypes of <u>Vibrio cholerae</u>: El Tor and classical.

Within each biotype there are two serotypes: Ogawa and Inaba. In the preliminary study the outer membrane was prepared from all these strains according to the method described by Schnaitman(19) and the membrane proteins were analysed by sodium dodecyl sulphate-polyacrylamids gel electrophoresis(SDS-PAGE). All these

strains contained a major protein of molecular weight 48,000. But they differed in composition and proportions of minor proteins. The outer membrane protein profile was influenced by the growth medium. A polypeptide of molecular weight 15,000 was observed in the outer membrane when Vibrio cholerae ogawa 395 (classical) were grown in peptone-water, whereas a protein of molecular weight 68, 000 appeared when grown in the synthetic medium. Under anzerobic growth conditions the proportions of the low molecular weight protein 13,000 was greatly enhanced. The outer membrane contained heat modifiable proteins as the polypeptides with molecular weights 41,000 and 37,000 disappeared when membrane proteins were disaggregated in sodium dodecyl sulphate at or above 60°C. Immunochemical studies showed that Vibrio cholerae possessed a protein antigen in the outer membrane which was common to all biotypes and serotypes. Thus, the antiserum raised against the outer membrane of one classical strain(Ogawa 395) produced immunoprecipitation against the outer membrane preparation from different biotypes and serotypes. Toxicity of the various cell envelope components such as lipopolysaccharide, the outer membrane proteins was studied in the mouse (20). It was observed that the outer membrane did not possess any toxicity

whereas the lipopolysaccharide component of Vibrio cholerae was found to be toxic.

3.

Rationale: There are several reasons which justify the present study. Firstly, the currently available whole cell vaccine against cholera has only limited effectiveness for a short duration. Hence the various cell surface components of Vibrio cholerae should be analysed in detail in order to develop new and improved immunogens. Membrane proteins comprise about 50% of the cell surface. Yet, very little is known about them. Therefore, there is good reason to analyse the outer membrane of Vibrio cholerae so as to (a) have a better understanding of the cell surface architecture and (b) explore these components as potential immunogens, first in animals and if promising, later in man.

Secondly, studies in mice indicate that membrane proteins of Vibrio cholerae are nontoxic whereas LPS, the other cell surface component, possess toxic properties. Also, the existing whole cell vaccine cause pain and fever in man. Hence it is desirable to develop an immunogen which would be nontoxic.

Thirdly, preliminary studies have demonstrated that a polypeptide of molecular weight 48,000 was present in the outer membrane of all biotypes and serotypes of <u>Vibrio cholerae</u>. Also, the antiserum to the outer membrane proteins of <u>Vibrio cholerae</u> Ogawa 395, a plassical strain, agglutinated <u>Vibrio cholerae</u> of all biotypes and serotypes. Hence there is a good rationale to develop an immunogen which would cross react with all biotypes and serotypes.

B. SPECIFIC AIMS:

- 1. To study the outer membrane proteins from several strains of <u>Vibrio cholerae</u> belonging to both biotypes and both serotypes so as to obtain a broad spectrum of the outer membrane protein profile.
- 2. To study the outer membrane protein profile of other enterctoxigence vibrios such as non-agglutinable vibrios (NAG's) and Vibrio parahaemolyticus.
- To immunise laboratory animals such as rabbits against the outer membrane proteins of <u>Vibrio cholerae</u>.
- 4. To examine the artigenic cross reactivity of the major outer membrane protein in severa strains of Enterobacteriacae by
 - a. bacterial agglutination
 - b. various imm unoelectrophoretic techniques.

- 5. To evaluate the protective capacity of the outer membrane proteins in adult rabbits against challenge with classical and El Tor biotypes of both Inaba and Ogawa serotypes.
- 6. To compare the efficacy of the outer membrane proteins of

 Vibrio cholerae as immunogens against the cholera vaccine and
 cholera toxoid.
- 7. To examine whether differences exist between the membrane protein profile of the multi-antibiotic resistant strains of Vibrio 'cholerae and those sensitive.
- 8. If the results of the above objectives are promising attempts will be made to study the immunogenecity of Shigelia and enterotoxigenic E. coli outer membrane proteins.

C. METHODS OF PROCEDURE

Bacterial strains:

The study will emphasize on the strains of <u>Vibrio cholerae</u> belonging to both the biotypes (El Tor and classical) and serotypes (Ogawa and Inaba). Also it will include strains from non-cholera vibrios such as NAG's and <u>Vibrio parahaemolyticus</u> and enteropathogenic Gram-negative bacteria such as <u>Shi tella</u>, <u>E</u>, <u>coli</u> and <u>Salmonella</u>.

Growth media:

The following media will be used to grow Vibrio cholerae:

- Peptone water: A 3% solution of peptone water, pH 7.4 would be prepared as directed by Burrows et al (29).
- 2. Semisynthetic or syncase: This medium will be prepared according to the procedure described by Finkelstein et al (21).
- 3. Synthetic: In this medium ingredients will be the same as those described in the semisynthetic medium except that casaminoacids will be replaced by 2.5 gms/liter of each of the following acids: glutamine, serine, aspartic acid and arginine.

Growth conditions:

- Aerobic: Cultures will be incubated with or without shaking at 37°C and harvested at the stationary phase of the growth.
- 2. Anaerobic: Media containing bile salts will be prepared by adding 1 g(2.2 mM) sodium deoxycholate to 1 liter of syncase.

 The medium will be prereduced for 24h in an atmosphere of H₂ and CO₂ and the growth will have to be maintained in Gas pak jars(BBL) in a similar atmosphere at 37°C for 16 h.

Preparation of the outer membrane :

Vibrio cholerae cultures (250 ml) will be grown at 37°C with shaking to a density of A_{600} 0.8 -- 1.00 and harvested at 12,000 xg for 15 min. at $0\text{-}4^{\circ}\text{C}$. The cell pellet will be resuspended in 25 ml of 0.1 M Tris-HC1, pH 7.8 and sheared at 4°C in a Waring blender (19,000 rev/min, 45 sec) to remove flagella as described for E. coli (22). The suspension will be diluted sixfold in the Tris-buffer and subjected to centrifugation at 12,000kg for 10 mic. The cell pellet will be resuspended in cold 0.75 M sucrose - 10 mM Tris- HC1, pH 7.8 (0.7 ml sucrose solution per 10 A600 units of original culture). The suspension will be transferred to an Erienmeyer flask containing lysozyme (2 mg/ml of ${\rm H_20},~0.05~{\rm ml/ml}$ of cell suspension) and the mixture incubated in ice for 2 min. The suspension will be diluted with 2 volumes of cold EDTA (1.5 mM) and kept at 4°C for 3 h. The spheroplast will be lysed by the osmotic shock by slowly pouring the suspension into 4 volumes of cold water with magnetic stirring and will be stirred for 10 min. in the cold. The total membrane fraction will be recovered from the osmotic lysate first by centrifugation at 12,000 kg for 15 min. at 2 -- 4°C to remove the unlysed cells and later by centrifuging the supernatant at 48,000 xg for 30 min. The pellet will be resuspended into

0.01 M Tris-HC1 (pH 7.8) containing 10 mM EDTA by a syringe and to be washed once with Tris-HC1 (0.01 M), pH 7.8 containing 5 mM MgC1₂. The inner membrane will be dissolved from the total membrane by extraction at 0°C for 20 min. with 2% Triton X-100 containing 5 mM EDTA described for E. coli by Schnaitman(19). The outer membrane will be recovered as a pellet.

Enzyme assay: To check the purity of the outer membrane preparation, the NADH-oxidase activity will be assayed as described by Osborn et al(23). The incubation mixture for the measurement of NADH-oxidase activity will contain 50 mM Tris-HCl, pH 7.5, 0.12 mM NADH, 0.2 mM dithiothreital and the membrane preparation (0.1-0.2 mg of protein) in a volume of 1.0 ml. The rate of decrease in absorbance will be measured at 340 nm at 25°C.

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SI)S-PAGE.

SDS-PAGE will be carried out according to the method of King and

Lamelli (24). The slab gels (10% acrylamide) will be case between

glass plates (15 x 15 cm) to a hight of 10 cm using spacers of

1.5 mm thick. The gel solution will be overlaid with water until

polymerization is completed. A stacking gel (3% acrylamide) of 1 cm

height will be applied on top of the analytical gel. Electrophoresis will

be performed at 30 mA until the tracking dye would reach the end of the gel.

The slab gels will be fixed by treating them with a solution of 45.4% methanol and 9.2% acetic acid in water. The gels will be stained with gentle shaking for 2 h in 0.025% Coomassic brilliant Blue R-250 dissolved in isopropenol (25%) and scetic acid (10%) and would be destained by shaking overnight in 10% acetic acid.

Unless otherwise stated, membrane proteins will be disaggregated by mixing an equal volume of sample buffer (0.125 M Trishydrochloride, pH 6.9, 4% SDS, 10% 2-mercaptomethanol, 0.002% bromophenol blue) with a sample containing 10 to 160 mg of protein. The mixture will be heated at 100°C for 3 min.

Isolation of the outer membrane proteins:

1. Gel filtration in the presence of sodium dodecvl sulphate:

Membrane proteins (ca. 800 mg) will be treated with 0.05 M

Tris/HC1 (80 ml, pH 7.00) containing 1% sodium dodecyl
sulphate (SDS) and 1 mM EDTA at 25°C for a period of

1 h. The dissolved material will be applied on to a column
of Sephadex G-200 and eluted at 25°C with 0.05 M Tris/HC1,

pH 7.00 containing 1% SDS, 1 mM EDTA and 0.02% sodium azide.

The flow rate will be 25 ml/h and 7.5 ml fractions are to be collected. Fractions under each peak are to be pooled, dialysed against several changes of sterile water and lyophilized.

The polyacrylamide gel section containing separated protein bands will be cut into pieces and macerated by passing through a syringe. Proteins will be eluted by shaking at 37°C into 10 volumes of 0.05 M NH₄ HCO₃ containing 1% SDS. After 6 h, the polyacrylamide fragments will be removed by centrifugation and then washed once with a small volume of elution buffer. The combined supernatants will be dialysed against SDS in order to remove the buffer originally present in the gel. Upon lyophillisation NH₄ HCO₃ will be removed leaving a protein-SDS mixture which will be utilised for further

Antisera:

studies.

Antisera against <u>Vibrio cholerae</u> membrane proteins will be prepared in rabbits by immunising each rabbit with 1 mg of <u>Vibrio cholerae</u>

Ogawa 395 total membrane, suspended in 0.5 ml of saline and an equal volume of Freund's incomplete adjuvant. Antigens will be

administered on days 0, 14, 28 and 42. Blood will be collected one week after the last injection. The antisers will be stored at 70°C until use.

Immunodiffusion:

The outer membrane proteins will be solubilised in the non-ionic detergent Tween 20. Briefly, one volume of a 0.10 M Tris-HC1 (pH 8.0) containing 5% Tween 20 will be added to 1 volume of the membrane suspension. The mixture will be shaken for a period of 2 hours at room temperature and will be centrifuged at 10,000 xg.

The supernatant will be subjected to immunodiffusion in 2% agarone.

Immunoelectrophoresis:

The outer membrane proteins, solibilised in Tween 20 as described above, will be subjected to immunoelectrophoresis in a barbital buffer, pH 8.2 in 2% agarose for 1 h and allowed to diffuse against antiserum to <u>Vibrio cholerae</u> total membrane.

Challenge studies:

Immunization: Rabbits are to be immunized subcutaneously in both flanks on days 0 and 7. They are to be challenged via ligated ileal loops on days 14 and 18.

Preparation of ligated ileal loops:

Heal loops are to be prepared according to the method of
De and Chatterje(25). Rabbits are to be fasted for 48 h to allow
elimination of fecal pellet. Each segment of the ligated fleum
will be challenged one balf milliliter of a vibrio suspension,
appropriately diluted in PBSG(phosphate buffered saline, pH 7.2
containing 0.1% gelatin). Each segment will be approximately
6 to 9 cm in length and each separated by an uninoculated segment
of about 2 cm. Coutrol loops will receive 0.5 ml of PBSG or
0.5 µg of cholera toxin in 0.5 ml of diluent. After 18 h the rabbits
are to be sacrificed and the fleum excised. Loops are to be
carefully measured and the ratio of the volume of fluid accumulated
(in milliliters) to the length of the segment (in centimeters) will
be calculated and expressed as the fluid accumulation(FA) ratio.

D. SIGNIFICANCE:

Successful completion of the proposed studies should considerably increase our knowledge about organisation of the cell wall of <u>Vibrio cholerae</u>. The studies will provide specific information on the presence of common protein antigen among various biotypes and serotypes of <u>Vibrio cholerae</u> as well as other enteric bacteria. The study might lead to the possibility of

developing a non-toxic immunogen which would provide protection against challenges with all biotypes and seretypes of Vibrio cholerae.

E. FACILITIES REQUIRED :

- 1. Office space: Office space required for the Principal Investigator.
- Laboratory space : Laboratory space required for experimental work.
- 3. Hospital resources : None
- 4. Animal resources: 100 rabbits.
- 5. Logistical support: none
- 6. Major items of equipments:
 - a. Ultracentrifuge
 - b. Electrophoretic apparatus for
 - i. i. Polyacrylamide gel electrophoresis
 - ii. Immunoelectrophoresis
 - iii. Crossed immunoelectrophoresis
- 7. Other specialized requirements:

F. COLLABORATIVE ARRANGEMENTS:

The principal investigator would maintain a collaborative research programme with the Max-Planck Institute für Immunbiologie, Freiburg, Germany which is very well equipped to perform analytical works on bacterial cell surface antigens. The principal investigator has discussed this possibility with the Director of the Max-Planck-Institute in person and would like to spend a few weeks there during the course of this study.

SECTION III - BUDGET A. DETAILED BUDGET

1. PERSONNEL SERVICES

NAME	POSITION	% TIME USED	ANNUAL BALARY	TAKA	DOLLAR
Dr. S. Kabir	Scientist	25%	105,000	26, 250	ash
Dr. A. Mahmood	Asso. Scientist	10%	71, 000	7, 100	ngagi
Mr, S. Ali	Technician	100%	26, 568	26, 568	æ.p
Mr. Shaffullab	* #	5%		1,000	aut.
		54. h. 6. a. 4.	<i></i>	60, 918	magnetical agricus por est program have registered and agricultural ag
		Sub tot		99, 340	Mandand or Tring Browning control of the State of the Sta

2. SUPPLIES AND MATERIALS

AND .	15,000	Tk.	Tk.	Reagents, chemicals
arinanan dari menenggan dan baran baran dari berapa dan baran dari berapa dan baran dari berapa dan baran dari	· · · · · · · · · · · · · · · · · · ·	And respectively.		
يونون د د د کافت پستوانسونيوسو پرسو	15, 000	Tk.	Sub total	
	15, 000		Sub total	

3.	EQUIPMENT
----	-----------

		_					
Sub	total	7	ľk.	**	4	6,	000
		40	موارد کرمور ترجمهٔ محمد الاستان بهمندی مروقه که مطابقات در	nga sa ata kananan mangan menangan mena	enter by drain	distriction of	garanta an maken di maken ayan baka da

- \$ 5,000

PATIENT HOSPITALISATION

None

5. OUTPATIENT CARE

None

6. ICDDR, B TRANSPORT

None

7. TRAVEL AND TRANSPORTATION OF PERSONS

International travel		TAKA	DOLLAR
Transport	1 meeting		2,000
Per diem	10 days		500
Collaborative work	50 days		2, 500
		and the country of the control of th	militarin territoria de proposación de la companya
	Sub total	Tk	\$ 5,000

8. TRANSPORTATION OF THINGS

Import of Equipments:

\$ 1,000

Local shipment

none

Sub total - \$ 1,000

9. RENT, COMMUNICATIONS AND UTILITIES

Postage

Telephone - none

Cable - none

Rent - none

Sub total Tk. 500.00

Tk. 500.00

10.	PRINTING AND REPRODUCTION	N					
	Printing forms			500			
	Special reproduction			2,000			,
	Publication costs				man and area	500	_{NG} in the second to
	Sub total		Special control of the control of th	2, 500	\$	500	maga mengap galam mengapa Mili malapi dan mengapa panta
,							
11,	OTHER CONTRACTUAL SERV	CER	_				
	None						
12.	CONSTRUCTION, RENOVATION	N AN	D AL	CERATIO	Nb		
	None						
13.	ANIMAL REQUIREMENT						
	100 rabbits		Tk.	12, 500			
,	Sub to	tal	Tk.	12, 500			

B. BUDGET SUMMARY

		Yoar	Your - 1			
	CATEGORY	TAKA	DOLLAR			
1.	Personnel	60, 918	+447)			
2.	Supplies	15, 000	ме ;			
3.	Equipment	en e	6,000			
4.	Patient hospitalisation	t/w				
5.	Outpatients care	was:	audi/-			
6.	ICDDR, B transport	-	tudó			
7.	Travel Persons	pop.	5,000			
8.	Transportation things	or .	1,000			
9.	Rent/Communication	500	-ree			
10.	Printing & reproduction	2, 500	500			
11.	Contractual service	•	esi			
12.	Construction	Von	#27			
Coresis de la Coresista de la Coresis de la	Animal requirement	12, 500	erino.			
*	Grand total	91, 418	12, 500			
•			6, 100			
		Total \$	18,600			

REFERENCES

- 1. Mosley, W.H., A.S. Benenson, and R. Barul. 1968. A serological survey for cholera antibodies in rural East Pakistan. 2. A comparison of antibody titres in the immunized and control populations of a cholera vaccine field-trial area and the relation of antibody titre to cholera cost rate. Bull. W.H.O. 40: 187-197.
- Cash, R.A. S.I. Music, J.P. Libonati, M.J. Snyder,
 R.P. Wenzel and R.B. Hornick. 1974. I. clinical, serologic and
 bacteriological responses to a known inoculum. J. Infect. Dis.
 129: 45-52.
- 3. Benenson, A.S. A. Saad, W.H. Mosley, and A. Ahmed. 1968.

 Serological studies in cholera. 3. Serum toxin neutralization rise
 in titre in response to infection with Vibrio cholerae and the level
 in the "normal population" of East Pakistan. Bull. W.H.O.

 38: 287-295.
- 4. Pierce, N.F. J.G. Banwell, R.B. Sack, R.C. Mitra and
 A. Mondel. 1970. Magnitude and duration of antitoxic response
 to human infection with <u>Vibric cholerae</u>. J. Infect. Dis. 121(Suppl):
 531-535.

- Levine, M. R. D. R. Nalin, J. P. Craig, D. Hoover,
 E. J. Bergquist, D. Waterman, H. P. Holley, R. B. Hornick,
 N. F. Pierce and J. P. Libonati. 1979. Transactions of the
 Royal Society of Tropical Medicine and Hygiene, 73: 3 9.
- 6. Mosley, W.H. W.M. McCormack, A. Ahmed,
 A.K.M.A. Chowdhury and R.K. Barni. 1969. Report of the

 1966-1967 cholera vaccine field in rural East Pakistan. Bull. W.H.O.
 40: 187-197.
- 7. Mosley, W. H. Woodward, W. E. Aziz, K. M. A. Hahman, A. S. M. M. Chowdhury, A. K. M. A. Ahmed, A. Feeley, J. C. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J. Infect. Dis. 121. Suppl. 51-59 (1970 b).
- 8. Azurin, J.C. A Crez, T.P. Pesigan, M. Alvero, T. Camena, R. Suplido, L. Ledezima and C.Z. Gomez. 1967. A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull. W.H.O. 37: 703-727.

- 9. Kennedy, J. R. and Richardson, S. H. 1969. Five structure of <u>Vibrio cholerae</u> during toxin production. Journal of Bacteriology. 100: 1393-1401.
- Neoh, S. H. and D. Rowley. 1972. Protection of infant mice against cholera by antibodies to three antigens of <u>Vibrio cholerae</u>.
 J. Infect. Dis. 126, 41-47.
- 11. Braun, V. 1975. Biochem. Biophys. Acta 415: 335-77.
- DiRionzo, J. M. Nakamura, K. and Inouye, M. 1978.

 The outer membrane proteins of gram-negative bacteria in biosynthesis, assembly and functions. Ann. Rev. Biochem. 47: 481-532.
- Barber, C. and E. Eylan. 1976. Cross-protection induced in mice by immunizations with proteins of related bacterial species.

 Zbl. Bakt. Hyg. I. Abt. Orig A. 234, 46-52.
- Hofstra, H. and J. Dankert. 1979. Antigenic cross-reactivity of major outer membrane proteins in enterobacterial species.

 Journal of in general Microbiology. 111, 293-302.

- 15. Kabir, S. Investigations of the outer membrane proteins of Salmonella typhimurium. Microbios. 20: 47-62.
- 16. Kussi, N. M. Nurminen, H. Saxen, M. Vattonen, and P. H. Makela, 1979. Immunization with major outer membrane proteins in experimental salmonellosis of mice. Infection and immunity, 25: 857-862.
- 17. Geyer, R. C. Galanos, O. Westphal and J. R. Gotecki, 1979.

 A lipopolysaccharide binding cell surface protein from Salmonella

 Minnesota. European Journal of Biochemistry. 98: 27-28.
- 18. Kabir, S. 1980. The composition and immunochemical properties of the outer membrane proteins of <u>Vibrio cholerae</u>. (manuscript in preparation).
- 19. Schnaitman, C. A. (1971) Solubilization of the cytoplasmic membrane of Escherichia coli. Triton X-100. Journal of Bacteriology.

 108: 545-552.
- 20. Burrows, W. G. M. Musteikis, N. B. Oza and N. K. Dutta. 1965.

 Cholera toxins: quantitation of the frog skin reaction and its
 relation to experimental enteric toxicity. J. Infect. Disease.

 115: 1-8.

- 21. Finkelstein, R.A. Attahsampunna, P. Chulasamya, M. and Charummethee, P. (1986). Pathogenesis of experimental cholera: biologic activities of purified procholeragen A. Journal of I Immunology. 96: 440-449.
- De Pamphilis, M. I., and J. Adler. 1971. Purification of intact flagella from Escherichia coli and Bactilus subtilis.

 Journal of Bacteriology. 105: 376-383.
- Osborn, M.J. Gander, J.E. Parisi, E. and Carson, J. (1972).

 Mechanism of assembly of the outer membrane of <u>Salmonella</u>

 typhimurium, Journal of Biological chemistry, 247: 3962-3972.
- 24. King, J. and U.K. Lamelli. 1971. Polypepticles of the tail fibres of bacteriophage T4. J. Mol. Biol. 62: 465-477.
- De, S.N. and D.N. Chatterje. 1953. An experimental study of the mechanism of action of <u>Vibrio cholerae</u> on the intestinal mucous membrane. J. Pathol. Bacteriol. 79: 131-140.